Navigation Links
Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019
Date:5/15/2012

Marketed Products in GI Carcinoid NETs, 2012 48Figure 26: Strategic Competitor Assessment of the Major Marketed Products in Pancreatic NETs, 2012 49Figure 27: Neuroendocrine Carcinoma Therapeutics Pipeline by Phase of Clinical Development, 2012 53Figure 28: Neuroendocrine Carcinoma Therapeutics – Clinical Pipeline by Mechanism of Action, 2012 55Figure 29: Technology Trends Analytic Framework of the Neuroendocrine Carcinoma Therapeutics Pipeline, 2012 56Figure 30: Technology Trends Analytic Framework of the Neuroendocrine Carcinoma Therapeutics Pipeline – Description, 2012 57Figure 31:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Region/Country, 2012 62Figure 32:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Phase, 2012 63Figure 33:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Trial Status, 2012 64Figure 34:Neuroendocrine Carcinoma Therapeutics– Clinical Trials by Overall Sponsors, 2012 65Figure 35: Neuroendocrine Carcinoma Therapeutics– Clinical Trials by Prominent Sponsors, 2012 66Figure 36:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Top Companies, 2012 67Figure 37:GI Carcinoids NETs Therapeutics – Implications for Future Market Competition, 2012 68Figure 38:Pancreatic NETs Therapeutics – Implications for Future Market Competition, 2012 69Figure 39:Neuroendocrine Carcinoma Therapeutics – Clinical Pipeline by Company, 2012 70Figure 40- GlobalData Market Forecasting Model 83

Companies mentioned

Advanced Accelerator Applications S.A

Novartis AG

F. Hoffmann-La Roche

Ipsen SA

To order this report:Therapy Industry:
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
2. Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients With Carcinoid/Neuroendocrine Tumors
3. Childhood Obesity Linked to Increased Risk of Hepatocellular Carcinoma in Adulthood
4. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
5. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
6. Targeted Gold Nanoparticles and Noninvasive Radio Fields Attacking One of the Deadliest and Least Curable Types of Cancer: Pancreatic Carcinoma
7. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
8. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
9. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
10. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 China Cord Blood Corporation (NYSE: CO) ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has filed its Annual Report ... Commission. The filed Form 20-F includes audited financial statements ... Form 20-F can be accessed by visiting the U.S. ...
(Date:7/30/2015)... July 30, 2015   GenoSpace , a ... interpretation and analysis of genomic and other biomedical ... has joined the company as Vice President of ... http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace partners with ... interpret, analyze and explore complex sets of genomic, ...
(Date:7/30/2015)... Diego , CA (PRWEB) , ... July 30, ... ... announced the successful completion of a field clinical study of its canine osteoarthritis ... developed together with Aratana Therapeutics (Kansas City, KS) and will be marketed in ...
(Date:7/30/2015)... , July 30, 2015 Ascendis Pharma ... that applies its innovative TransCon technology to address ... results from a six-month Phase 2 study to ... Growth Hormone in 53 treatment-naïve, pre-pubertal children with ... are extremely pleased with the top-line results from ...
Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... Oct. 3 NPS Pharmaceuticals,Inc. (Nasdaq: NPSP ) ... its,cash tender offer with respect to its outstanding $171.8 ... due 2008. Under,the amended terms of the tender offer, ... of the outstanding convertible notes at a,purchase price, per ...
... RICHMOND, Calif., Oct. 3 Sangamo BioSciences,Inc. (Nasdaq: ... president of research, will provide an update on the ... of the,company,s business strategy at 12:45pm (PT) on Wednesday, ... The presentation will be webcast live and may ...
... WALTHAM, Mass., Oct. 3 Thermo Fisher,Scientific ... that it has acquired Priority,Solutions International, a ... healthcare industries, following anti-trust clearance.,Priority Solutions was ... of approximately $95 million in 2006, Priority,Solutions ...
Cached Biology Technology:NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007 2NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007 3Sangamo BioSciences to Present at the 2007 BIO InvestorForum 2Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services 2Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services 3Thermo Fisher Scientific Acquires Logistics Provider to Strengthen Clinical Trials Management Services 4
(Date:7/9/2015)... , July 07, 2015 ... the addition of the "Biometrics for Banking; ... 2015-2020" report to their offering. ... contributor to this growth and the forecast is ... in revenue for companies involved in delivering biometric ...
(Date:7/8/2015)... NEW YORK , July 8, 2015  BD ... announced BD & Guidepoint Mentor, a new ... to Guidepoint,s expert network services. BD ... technologies to improve healthcare delivery and outcomes and, with ... start-up entrepreneur will be able to directly engage with ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... (NIST), in collaboration with the Centers for Disease Control ... Materials (SRMs) for measurements of human exposure to environmental ... check the accuracy of tests and analytic procedures, the ... measures for emerging environmental contaminants such as perchlorate, a ...
... outside Seville, in the desert region of Andalucia, Spain, sits ... giant mirrors rippling outward. More than 600 of these mirrors, ... sun throughout the day, concentrating its rays on the central ... enough to power 6,000 homes. The sprawling site, ...
... different immunological mechanisms ensure the successful establishment and maintenance ... adverse pregnancy outcomes. In a review published in ... Institute of Life Science, College of Medicine at Swansea ... obesity on the inflammatory responses in tissues of both ...
Cached Biology News:NIST releases 2 new SRMs for monitoring human exposure to environmental toxins 2MIT research: A new sunflower-inspired pattern increases concentrated solar efficiency 2MIT research: A new sunflower-inspired pattern increases concentrated solar efficiency 3Inflammation may link obesity and adverse pregnancy outcomes 2
... Linkage: This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... Mouse C2C12 cells were cultured in DMEM and ... In order to keep the antigens in their ... The cells are arrayed on a 12-well (5 ... specifically treated to enhance cellular attachment and to ...
... (PI) is a fluorescent nucleic acid dye ... As a nuclear counterstain, propidium iodide ... in color. The fluorescent red color ... fluorochromes such as FITC, Cy2 or AMCA. ...
... parameter assay for mitochondrial membrane potential ... caspases are detected by carboxyfluorescein (FAM)-labelled ... cell-permeable, non-cytotoxic and bind covalently to ... At the same time the mitochondrial ...
Biology Products: